ADRA2A is a suppressor of the basal-like/squamous subtype and reduces disease aggressiveness of pancreatic cancer. ADRA2A is a suppressor of the basal-like/squamous subtype and reduces disease aggressiveness of pancreatic cancer

Pancreatic cancer is a heterogeneous disease and consists of distinct subtypes. Here, we investigated candidate suppressor genes of the basal-like/squamous subtype, a more aggressive molecular subtype of pancreatic ductal adenocarcinoma (PDAC). Through an integrated transcriptome analysis, we identified the ADRA2A, as being downregulated in the basal-like/squamous PDAC using a discovery and validation approach. ADRA2A downregulation is associated with decreased patient survival. The goal of this study was to identify ADRA2A-induced molecular signatures in PDAC. Overall design: RNA was isolated from human PDAC cell lines (CFPAC-1 with empty vector control; n = 4, CFPAC-1 with ADRA2A transgene overexpression; n = 4) using TRIzol method. The mRNA profiles of the human PDAC cell lines were generated by deep sequencing using Illumina NextSeq.

胰腺癌是一种异质性疾病，存在多种明确的亚型。本研究聚焦于胰腺导管腺癌（pancreatic ductal adenocarcinoma, PDAC）中侵袭性更强的基底样/鳞状分子亚型，对其候选抑癌基因开展探究。通过整合转录组分析并采用发现-验证研究策略，本研究鉴定出ADRA2A在基底样/鳞状PDAC中表达下调。ADRA2A表达下调与患者生存期缩短显著相关。本研究的核心目标为鉴定PDAC中ADRA2A调控的分子特征谱。总体实验设计：采用TRIzol法从人PDAC细胞系中提取总RNA，其中包括转染空载体的CFPAC-1细胞（n=4）以及过表达ADRA2A转基因的CFPAC-1细胞（n=4）；随后通过Illumina NextSeq测序平台对上述细胞系进行深度测序，获取其mRNA表达谱。